Effects of direct oral anticoagulants (DOAC) on surgical procedures in oral and maxillofacial surgery

Recruiting

• Conditions: D68.3; T81.0; K08.88; D48.5; C44.3; Haemorrhagic disorder due to circulating anticoagulants; Haemorrhage and haematoma complicating a procedure, not elsewhere classified; Skin; Skin of other and unspecified parts of face

• Registration Number: DRKS00027934
• Lead Sponsor: niklinik FreiburgKlinik für Mund-, Kiefer- und Gesichtschirurgie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-01-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1400

Inclusion Criteria

Patients 18 years and older.
Patients who are being treated with a direct oral anticoagulant (DOAC) due to a pre-existing condition and are undergoing a surgical procedure under inpatient conditions at the Department of Maxillofacial Surgery. Inclusion of all consecutive patients starting in 2012.

Exclusion Criteria

Other solitary congenital or acquired coagulation disorders such as von Willebrandt-Jürgens syndrome, liver cirrhosis.
Therapy with platelet aggregation inhibitors alone.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Occurrence of postoperative bleeding or thromboembolic event after surgical treatment under inpatient conditions and concurrent therapy (including paused) with direct oral anticoagulants (DOAC).

Secondary Outcome Measures

Name	Time	Method
Review of guideline-compliant quality of care and therapy with DOACs (indication, contraindications, dosage, therapy interruption/modification) according to the surgical extent of therapy and the patients' pre-existing and concomitant diseases.